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Abstract 
Sphingolipids (SLs) are composed of fatty acids and a polar head group derived from L-serine. SLs are 
essential components of all eukaryotic and many prokaryotic membranes but sphingosine 1-phosphate (S1P) 
is also a potent signalling molecule. Recent efforts have sought to inventory the large and chemically complex 
family of SLs (LIPID MAPS Consortium). Detailed understanding of SL metabolism may lead to therapeutic 
agents specifically directed at SL targets. We have studied the enzymes involved in SL biosynthesis; later 
stages are species-specific, but all core SLs are synthesized from the condensation of L-serine and a fatty acid 
thioester such as palmitoyl-CoA that is catalysed by serine palmitoyltransferase (SPT). SPT is a pyridoxal 5′-
phosphate (PLP)-dependent enzyme that forms 3-ketodihydrosphingosine (3-KDS) through a decarboxylative 
Claisen-like condensation reaction. Eukaryotic SPTs are membrane-bound multi-subunit enzymes, whereas 
bacterial enzymes are cytoplasmic homodimers. We use bacterial SPTs (e.g. from Sphingomonas) to probe 
their structure and mechanism. Mutations in human SPT cause a neuropathy (HSAN1), a rare SL metabolic 
disease. How these mutations perturb SPT activity is subtle and bacterial SPT mimics of HSAN1 mutants 
affect the enzyme activity and structure of the SPT dimer. We have also explored SPT inhibition using various 
inhibitors (e.g. cycloserine). A number of new subunits and regulatory proteins that have a direct impact on 
the activity of eukaryotic SPTs have recently been discovered. Knowledge gained from bacterial SPTs sheds 
some light on the more complex mammalian systems. In the present paper, we review historical aspects of the 
area and highlight recent key developments. 
 
Introduction 
SLs are one of eight categories of lipid of the LIPID MAPS classification system 
[1]
. Mammalian cells produce 
a vast array of SLs that function not only as structural elements of cellular membranes, but also as potent 
bioactive signalling molecules (Scheme 1). They comprise a sphingoid base that can be amide-linked to a 
second fatty acid to give ceramides and derivatized further by the addition of a headgroup such as a sugar or 
phosphate. Structural diversity in the SL family arises from variations in the acyl chains and the large number 
of possible headgroups 
[2]
. 
SLs are also produced by plants, fungi and some bacteria, but the biosynthetic pathway in each can differ. For 
example, sphingosine is the major sphingoid base found in mammals, whereas phytosphingosine is found in 
fungi (Figure 1A). SL biosynthesis can also vary between species; the yeast Saccharomyces cerevisiae 
produces solely complex SLs containing a phosphoinositol headgroup, whereas Pichia pastoris produces both 
phosphoinositol-based and glucosylceramide-based GSLs (glycosphingolipids) 
[3]
. SL biosynthesis also varies 
between bacterial species. GSLs are ceramides isolated from the Gram-negative bacterium Sphingomonas 
paucimobilis that contain either saturated and unsaturated sphingoid bases derived from palmitic acid that are 
attached to a second fatty acyl group derived from myristic acid 
[4]
. 
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Scheme 1. The series of enzymatic steps that makes up SL de novo biosynthesis in mammals. SPT (green) catalyses the first rate-limiting step; the 
enzyme names for other major steps in the pathway are in red. 
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By comparison, SLs in the dental pathogenPorphyromonas gingivalis contain unusual iso-branching on both 
the sphingoid base and the amide-linked fatty acid 
[5]
. Therefore some organisms express anabolic enzymes 
for SL biosynthesis not found in others. Conversely, the first enzymatic step of de novo SL biosynthesis is 
common in all SL-producing organisms studied to date (Figure 1A). This step is carried out by the pyridoxal 
5′-phosphate (PLP)-dependent serine palmitoyltransferase (SPT) [6]. The SPT gene is indispensable and thus 
can be used as a marker for identifying species of the SL-producing bacterium Sphingomonas in 
environmental samples 
[7]
. SPT catalyses a Claisen-like condensation between L-serine and an acyl (typically 
palmitol) coenzyme A (CoASH) or an acyl-ACP (acyl-carrier protein) thioester substrate, to form the first 
sphingolipid metabolite 3-ketodihydrosphingosine (3-KDS) (Figure 1B). Hence this condensation reaction 
forms the sphingoid base or LCB (long-chain base) found in all subsequent intermediate SLs and complex 
SLs in the organism. An abridged version of the SPT enzymatic reaction shown in Figure 2(A) indicates three 
important intermediates: (I) the holo-form or internal aldimine of the enzyme with PLP cofactor bound to the 
active-site Lys
265
 (S. paucimobilis SPT) numbering] via a Schiff base; (II) the external aldimine with L-serine 
following transimination; and (III) the quinonoid intermediate (carbanion equivalent) following deprotonation 
at Cα that attacks the incoming thioester substrate. 
 
 
Figure 1. The key step in sphingolipid biosynthesis is conserved across all organisms studied to date. (A) 
The de novo pathway for SL biosynthesis can differ between species, but the first step, catalysed by SPT, is 
common across mammals, plants, fungi and bacteria. 3-KDS, 3-ketodihydrosphingosine; P-CoA, palmitoyl-
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CoA. (B) All SPTs condense L-serine with a fatty acyl derived from either an acyl-CoA substrate or an acyl-
ACP substrate. 
 
 
Figure 2. Mechanism and structure of bacterial SPT. (A) Abridged mechanism for the reaction catalysed 
by SPT. The reaction is dependent on its active-site PLP cofactor. (B) Structural comparison of the SPT 
internal aldimine with the L-serine-bound external aldimine form. 
 
Three-dimensional structures of bacterial SPTs 
SPT is a member of the alpha-oxoamine synthase (AOS) family of PLP-dependent enzymes and is classified 
in the fold-type I family of which aspartate aminotransferase is the prototype 
[8]
. Three-dimensional crystal 
structures of several AOS enzymes have been solved including 8-amino-7-oxononanoate synthase (AONS) 
[9]
, 
5-aminolaevulinate synthase (ALAS) 
[10]
, 2-amino-3-oxobutyrate:CoA ligase (KBL) 
[11]
 and cholera quorum-
sensing autoinducer-1 synthase (CqsA) 
[12,13]
. Isolation of a homodimeric and water-soluble native SPT from 
the Gram-negative bacterium S. paucimobilis (SpSPT) 
[14]
 paved the way for structural studies on this enzyme 
(Table 1). The first crystal structure of the holoenzyme at 1.3 Å resolution (PDB code 2JG2) revealed a 
symmetrical SPT homodimer with PLP cofactor bound to a conserved Lys265 in each subunit 
[15]
 (Figure 2B). 
The PLP cofactor is held in place via several interactions with active-site residues (at the dimeric interface 
from both subunits), the most important being π-stacking between the PLP pyridine ring and a conserved 
His159. Correct positioning of the PLP cofactor in the active site is vital, since addition of the L-serine 
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substrate to SPT His159 mutants led to an abortive transamination reaction 
[16]
. Subsequent studies captured 
the enzyme with the L-serine substrate bound as an external aldimine Schiff base following transimination at 
Lys265 
[17]
. In this structure, a non-conserved arginine residue (Arg378) had undergone a large swing into the 
active site to interact with the carboxy moiety of the PLP:L-serine external aldimine substrate (Figure 2B). 
Active-site arginine residues are crucial for recognition of the L-serine carboxy moiety during the catalytic 
cycle in this SPT homologue. In fact, mutation of a second active-site arginine residue in Sphingomonas 
wittichii SPT (SwSPT) (Arg370 equivalent to Arg390 in SpSPT), conserved in all SPTs and across the AOS 
family, resulted in an enzyme that could not form the subsequent quinonoid intermediate (species (III) in 
Figure 2A) in the presence of a palmitoyl-CoA analogue 
[18]
. 
 
Table 1. List of bacterial SPT homodimers and the current components of the human and yeast SPT 
complexes. 
SPT homodimer UniProt number Reference(s) 
Bacterial SPT homodimers 
  
 Sphingomonas paucimobilis Q93UV0 [14,15] 
 Sphingomonas wittichii A5VD79 [20] 
 Sphingobacterium multivorum A7BFV6 [19,22] 
 Sphingobacterium spiritivorum A7BFV7 [22] 
 Bdellovibrio stolpii A7BFV8 [22] 
 Bacteroides fragilis Putative [27] 
Eukaryotic SPT complexes 
  
 Human 
  
  LCB1 O15269 [34] 
  LCB2 O15270 [33,34] 
  LCB3 Q9NUV7 [31] 
  Small subunit A Q969W0 [47] 
  Small subunit B Q8NFR3 [47] 
  ORMDL1/ORMDL2/ORMDL3 Q9P0S3, Q53FV1, Q8N138 [48,50] 
 Saccharomyces cerevisiae 
  
  LCB1 P25045 [29,32,35] 
  LCB2 P40970 [32] 
  Tsc3 Q3E790 [23] 
  ORM1/ORM2 P53224, Q06144 [48–50] 
 
The three-dimensional structures of two other SPT homologues, Sphingobacterium multivorum SPT (SmSPT, 
38% homology) and SwSPT (70% sequence identity), have since been elucidated. The external aldimine form 
ofSmSPT revealed an enzyme with an architecture very similar to that of SpSPT 
[19]
. One major difference was 
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that the carboxy group of the PLP:L-serine external aldimine formed was bound via two water molecules to 
two residues (Ser81 and Met271) on the opposite monomer, indicating that structural variations occur at the 
active site among homologous SPTs. Elucidation of the holoenzyme structure of SwSPT, from the dioxin-
degrading bacterium S. wittichii, uncovered further variations 
[20]
. For example, the entrance to the active site 
is wider than in its SpSPT homologue, suggesting that SwSPT may utilize a larger acylated-ACP thioester 
substrate rather than an acyl-CoA thioester. This prediction is strengthened by the fact that a gene encoding a 
putative bacterial Type II ACP resides immediately upstream of the SwSPT gene. Phylogenetic analysis of 
AOS enzymes has since found six bacterial SPT genes, including SwSPT, associated with ACP genes 
[21]
. 
 
Other bacterial SPT isoforms 
Along with the structural characterization of SPTs from the Sphingomonas strains described above, other 
SPTs have been characterized in terms of PLP-binding and substrate specificity from bacterial species 
including S. multivorum, Sphingobacterium spiritivorum and Bdellovibrio stolpii (see Table 1) 
[22]
. The PLP 
spectrum for each of these homologues was different from their S. paucimobilis counterpart. The SPTs from S. 
multivorum and B. stolpiiwere found to be peripheral proteins associated with the inner cell membrane, and 
therefore may more closely resemble the endoplasmic reticulum (ER)-bound eukaryotic SPTs. Furthermore, 
the SPT from B. stolpii displayed substrate inhibition by palmitoyl-CoA, a characteristic also found in the 
yeast 
[23]
 and mammalian SPTs 
[24–26]
. 
Recently, a study investigating the function of SLs in the gut-dwelling commensal bacterium Bacteroides 
fragilissuggested that SLs play a key role in survival strategies that allow the bacterium to persist under harsh 
conditions in the intestine 
[27]
. Bacterial cultures grown in the presence of the SPT inhibitor myriocin were 
more susceptible to stressful conditions, suggesting a role for SLs in survival. Also in this study, a putative 
SPT gene was identified in B. fragilis by BLAST search 
[27]
. Studies in our laboratory have confirmed that a 
purified recombinant version of this enzyme has SPT activity (Bower, Lowther, Campopiano et al, 
unpublished data). Kinetic evaluation revealed an overall slower turnover compared with SPTs from 
Sphingomonasstrains, as well as substrate inhibition by the acyl-CoA substrate similar to the SPT from B. 
stolpii. 
 
Inhibitors of SPT 
Several natural products (e.g. myriocin) have been identified as potent SPT inhibitors (Scheme 2) and are 
routinely used as ‘blockers’ of sphingolipid biosynthesis in cells. Surprisingly, few complete investigations 
into the exact mechanism of inhibition by each have been undertaken. We previously carried out a detailed 
study on inhibition of SPT by the antibiotic L-cycloserine. This broad-spectrum inhibitor usually disables its 
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target by forming an irreversible 3-hydroxyisoxazole:PLP adduct at the active site of several PLP-dependent 
enzymes such as alanine aminotransferase. However, prolonged incubation with SPT resulted in formation of 
pyridoxamine 5′-phosphate (PMP) and a small aldehyde product, β-amino-oxyacetaldehyde, both observed at 
the enzyme active site using X-ray crystallography and confirmed by MS 
[28]
. Elucidation of the structure of 
another SpSPT crystal grown in the presence of cycloserine revealed an elongated Lys265 side chain, in 
keeping with in situ modification by the cycloserine-generated aldehyde (Lowther, Naismith, Campopiano et 
al work). Studies into the mechanism of inactivation by the SPT inhibitors L-penicillamine, β-chloro-L-
alanine and myriocin are ongoing. 
 
 
Scheme 2. Natural product inhibitors of SPT. 
 
HSAN1 and deoxy-SLs 
It is thought that human SPT contains a core heterodimer that spans the outer membrane of the ER [28] 
comprising a “non-PLP-binding” LCB1 subunit (encoded by the SPTLC1 gene) together with a PLP-
containing LCB2 subunit (encoded by either SPTLC2 or SPTLC3). Here we describe LCB1 as not be able to 
bind PLP but this has yet to be proven since the PLP binding capacity of each subunit has not been analysed. 
We infer this from sequence homology/alignment studies; LCB2 contains all of the residues conserved among 
AOS family members involved in PLP binding and catalysis, i.e. a key lysine residue, two histidine residues 
and an aspartate residue, whereas LCB1 has none of these residues. Nevertheless, LCB2 is not expressed (and 
may not be stable) in the absence of LCB1, so the active catalytic SPT complex is thus a LCB1/LCB2 
heterocomplex. Whether LCB1 contributes catalytic residues to the PLP active site remains to be determined. 
Specific mutations identified in either SPTLC1 or SPTLC2 cause a rare genetic disorder called hereditary 
sensory and autonomic neuropathy type 1 (HSAN1) 
[37–39]
. Three-dimensional structures of two bacterial 
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SpSPT mimics, containing mutations similar to those identified in the LCB1 subunit of HSAN1 patients, 
revealed subtle structural changes at the enzyme active site 
[17]
. Dunn and colleagues showed that yeast or 
CHO cells expressing human heterotrimeric SPT (an LCB1–LCB2 heterodimer along with an ssSPT small 
subunit that is required for optimal SPT activity, see below) carrying the HSAN1-causing mutation (C133W) 
in the LCB1 subunit gave rise to an enzyme with enhanced ability to condense L-alanine with the acyl-CoA 
substrate 
[40]
. It therefore appears that HSAN1 mutations cause structural perturbations in the human enzyme, 
resulting in an altered specificity for the amino acid substrate. This relaxed specificity for amino acid substrate 
is consistent with the ‘gain-of-function’ phenotype of elevated levels of deoxysphingoid bases (deoxy-LCBs) 
arising from condensation of alanine and glycine with palmitoyl-CoA that is observed in HSAN1 patients and 
in HSAN1 transgenic mice 
[41]
. 
The absence of the C1-OH in the deoxy-LCBs precludes phosphorylation by LCB kinase and degradation by 
the LCB-phosphate lyase in the only known pathway for LCB degradation. This may be in keeping with a late 
onset of disease in HSAN1 patients, i.e. these lipids gradually accumulate to toxic levels over time. It is also 
interesting to note that deoxysphingoid bases were also observed in ‘healthy’ cells, suggesting that wild-type 
SPT has some degree of amino acid substrate freedom to generate these lipids normally. An exciting 
promising pilot study results suggest that a treatment may be on the horizon for HSAN1 sufferers. A new 
report shows that oral administration of the natural substrate L-serine could compete with L-alanine and 
glycine, prevented accumulation of deoxy-SLs and improved HSAN1 symptoms 
[42]
. 
It is important to stress that deoxy-SLs are natural metabolites that occur at low concentrations in all 
mammalian cells with a wild-type SPT. For example, deoxysphinganine was identified in kidney cells 
following addition of the ceramide synthase (CerS) inhibitor fumonisin B1 
[43]
. More recently, deoxyceramide 
has been found attached to an isolated human CD1b receptor 
[44]
. Specific functions for deoxy-SLs are still 
unknown and, because they cannot be phosphorylated, the mechanism by which they are degraded or removed 
from the cell has yet to be revealed. This will be a particular interesting avenue of study, since it appears that 
their accumulation over a long period of time causes cytotoxicity in HSAN1. Further research is also required 
to understand the natural promiscuity of wild-type SPT and whether this phenomenon is unique to SPT among 
all AOS enzymes. 
 
Identification of new subunits and regulators of the eukaryotic SPT complex 
The SPT complex from higher organisms appears to comprise a core LCB1/LCB2 heterodimer (Table). The 
PLP-containing LCB2 subunit carries out the condensation reaction and although the LCB1 subunit appears to 
lack the residues that bind PLP it is still required for activity 
[38]
. Hornemann et al identified a second isoform 
of LCB2 (LCB3, encoded by the SPTLC3 gene) that is expressed only in certain tissues.
[31]
 These two 
isoforms are functionally redundant in plants 
[45]
, but may have distinct functions in mammals since mice 
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lacking the Sptlc2 gene were embryonic lethal 
[46]
. It is interesting that some higher eukaryotes have two 
LCB2-like isoforms and others (e.g.Drosophila) have only one. Identification of novel components of SPT 
other than the core LCB1/LCB2 heterodimer has meant that the current model of the human SPT complex has 
advanced greatly in recent years. A third small subunit (Tsc3) associated with the heterodimer and required 
for maximal SPT activity was initially found by Dunn and colleagues in yeast 
[23]
, but bioinformatic 
approaches failed to identify candidate activators of the LCB1–LCB2 heterodimers from higher eukaryotes. 
However, poor correlation of SPT activity with increased SPTLC1/SPTLC2expression in mammalian cells and 
the failure to reconstitute SPT activities comparable with those in mammalian microsomes upon expression of 
mammalian SPTLC1 and SPTLC2 in yeast led Dunn and her collaborators to search for an additional factor 
similar to the activity-enhancing Tsc3 subunit they had found previously in yeast 
[47]
. Intriguingly, two novel 
small subunits (ssSPTa and ssSPTb) with no homology with Tsc3p were identified. Either of these small 
subunits can enhance activity >10-fold when bound to the LCB1/LCB2 (SPTLC1/SPTLC2 
orSPTLC1/SPTLC3) heterodimer. Furthermore, these small activating subunits of SPT also confer distinct 
specificities for acyl-CoA substrates. The recent exciting discovery by two independent groups (led by 
Jonathan Weismann 
[48]
 and Amy Chang 
[49]
) that the yeast ORM (orosomucoid) 1/ORM2 proteins also 
associate with and negatively regulate SPT activity has added an additional layer of complexity and prompted 
the authors to coin the term “SPOTS” complex [serine palmitoyltransferase, ORM1/2, Tsc3, Sac1 
(phosphatase)] to incorporate these novel components (Table). The ORMDL (orosomucoid-like) proteins are 
part of a family of endoplasmic reticulum proteins that were found to play a role in lipid homoeostasis and 
control of protein quality and trafficking 
[50]
. The ORMs themselves are controlled in yeast through 
phosphorylation various kinases and Sac1 phosphatase
 [51]
. It appears that the human ORMDL1/2/3 
homologues also interact with the LCB1/LCB2 heterodimers (and associated ssSPT, ORM and Sac1 
subunits??) embedded in the membrane
 [48]
 raises further questions about the organization and regulation of 
SPT. Exactly how the cellular sphingolipid/ceramide levels are relayed back to this SPOTS complex to turn it 
on and off is not clear. Detailed studies of the topological organization and interactions between the 
components of the SPOTS complex will shed light on how these components interact to insure that this 
committed and rate-limiting enzyme of SL synthesis is properly regulated. 
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